REG - AOTI, Inc. - Result of AGM

AotiAnnouncement

21/05/2026 11:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260521:nRSU3000Fa&default-theme=true

RNS Number : 3000F  AOTI, Inc.  21 May 2026

21 May 2026

AOTI, Inc. (the "Company" or "Group" or "AOTI")

Result of Annual General Meeting

The Annual General Meeting of AOTI, Inc. was held at the offices of Burges
Salmon, 6 New St Square, London, EC4A 3BF on 21 May 2026 at 10:00 a.m.

All 12 resolutions put to members were passed on a poll. Resolutions 1 to 11
were passed as ordinary resolutions and Resolution 12 was passed as a special
resolution.

The number of votes cast for and against each of the resolutions proposed, and
the number of votes withheld were as follows:

 

 Resolution                                                                     Votes for   %       Votes against  %     Votes withheld
 Resolution 1 (Ordinary)                                                        71,546,968  100.00  0              0.00  891,488

 To receive the Company's annual report and accounts for the year ended 31
 December 2025, together with the Directors' and Auditor's Report thereon.
 Resolution 2 (Ordinary)                                                        72,290,728  99.80   147,728        0.20  0

 To approve the Directors' Remuneration Report for the year ended 31 December
 2025.
 Resolution 3 (Ordinary)                                                        72,290,728  99.80   147,728        0.20  0

 To approve the Directors' Remuneration Policy for the year ended 31 December
 2025.
 Resolution 4 (Ordinary)                                                        71,564,669  98.79   873,787        1.21  0

 To re-appoint Douglas Le Fort as a director of the Company.
 Resolution 5 (Ordinary)                                                        72,438,456  100.00  0              0.00  0

 To re-appoint Michael Griffiths as a director of the Company.
 Resolution 6 (Ordinary)                                                        72,290,728  99.80   147,728        0.20  0

 To re-appoint Anthony Bourne as a director of the Company.
 Resolution 7 (Ordinary)                                                        72,438,456  100.00  0              0.00  0

 To re-appoint Richard Cotton as a director of the Company.
 Resolution 8 (Ordinary)                                                        72,438,456  100.00  0              0.00  0

 To re-appoint Ceri Morgan as a director of the Company.
 Resolution 9 (Ordinary)                                                        72,438,456  100.00  0              0.00  0

 To re-appoint Jayesh Pankhania as a director of the Company.
 Resolution 10 (Ordinary)                                                       72,438,456  100.00  0              0.00  0

 To re-appoint Grant Thornton (Ireland) as auditor of the Company.
 Resolution 11 (Ordinary)                                                       72,438,456  100.00  0              0.00  0

 To authorise the Directors to determine the fees payable to the auditor.
 Resolution 12 (Special)                                                        72,290,728  99.80   147,728        0.20  0

 To disapply statutory pre-emption rights for the purpose of financing or
 refinancing a transaction.

 

As at 21 May 2026, there were 106,359,163 ordinary shares in issue.
Shareholders are entitled to one vote per share. Votes withheld are not votes
in law and so have not been included in the calculation of the proportion of
votes for and against a resolution.

The full text of each resolution is available in the Notice of Annual General
Meeting, published on our website.

ENDS

 

 AOTI, INC.

 Dr. Mike Griffiths, Chief Executive Officer         +44 (0)20 3727 1000

 Jayesh Pankhania, Chief Financial Officer           ir@aotinc.net

 Peel Hunt LLP (Nominated Adviser and Joint Broker)

 Dr. Christopher Golden, James Steel                 +44 (0)20 7418 8900

 Panmure Liberum Limited (Joint Broker)              +44 (0)20 3100 2000

 Emma Earl, Will Goode, Mark Rogers

 Rupert Dearden

 FTI Consulting (Financial PR & IR)                  +44 (0)20 3727 1000

 Ben Atwell, Simon Conway,                           AOTI@fitconsulting.com

 Natalie Garland-Collins

 

ABOUT AOTI, INC.

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and
Galway, Ireland, providing innovative solutions to resolve severe and chronic
wounds worldwide. Its products reduce healthcare costs and improve the quality
of life for patients with these debilitating conditions. The Company's
patented non-invasive Topical Wound Oxygen (TWO(2)(®)) therapy has
demonstrated in differentiating, robust, double-blinded randomized controlled
trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the
recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88
per cent reduction in hospitalizations and 71 per cent. reduction in
amputations over 12 months. TWO(2)(®) therapy can be administered by the
patient at home, improving access to care and enhancing treatment compliance.
TWO(2)(®) therapy has received regulatory clearance from the US (FDA),
Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical
Products Administration, Australia (TGA) and in Saudi Arabia.
TWO(2)(®) therapy has also recently received positive coverage
recommendations from the Federal Joint Committee (G-BA) in Germany and
National Institute for Health and Care Excellence (NICE) in the United
Kingdom. Also see www.aotinc.net (http://www.aotinc.net/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSEEFSFEMSEFI



            Copyright 2019 Regulatory News Service, all rights reserved